These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 37235572)
41. Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. Mizuno T; Yoshida T; Sunami K; Koyama T; Okita N; Kubo T; Sudo K; Shimoi T; Ueno H; Saito E; Katanoda K; Shibata T; Yonemori K; Okusaka T; Boku N; Ohe Y; Hiroshima Y; Ueno M; Kuboki Y; Doi T; Nakamura K; Kohno T; Yatabe Y; Yamamoto N Jpn J Clin Oncol; 2021 Dec; 51(12):1757-1760. PubMed ID: 34622931 [TBL] [Abstract][Full Text] [Related]
42. Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy. Yoshii Y; Okazaki S; Takeda M Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440540 [TBL] [Abstract][Full Text] [Related]
43. Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. Dong OM; Poonnen PJ; Winski D; Reed SD; Vashistha V; Bates J; Kelley MJ; Voora D Value Health; 2022 Apr; 25(4):582-594. PubMed ID: 35365302 [TBL] [Abstract][Full Text] [Related]
44. Association between Family Caregivers' Satisfaction with Care for Terminal Cancer Patients and Quality of Life of the Bereaved Family: A Prospective Pre- and Postloss Study. Morishita-Kawahara M; Tsumura A; Aiki S; Sei Y; Iwamoto Y; Matsui H; Kawahara T J Palliat Med; 2022 Jan; 25(1):81-88. PubMed ID: 34348046 [No Abstract] [Full Text] [Related]
45. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice. Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376 [TBL] [Abstract][Full Text] [Related]
46. Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers. Hagio K; Kikuchi J; Takada K; Tanabe H; Sugiyama M; Ohhara Y; Amano T; Yuki S; Komatsu Y; Osawa T; Hatanaka KC; Hatanaka Y; Mitamura T; Yabe I; Matsuno Y; Manabe A; Sakurai A; Ishiguro A; Takahashi M; Yokouchi H; Naruse H; Mizukami Y; Dosaka-Akita H; Kinoshita I Cancer Sci; 2023 Aug; 114(8):3385-3395. PubMed ID: 37208840 [TBL] [Abstract][Full Text] [Related]
47. [Challenges in Expert Panel]. Yachida S Gan To Kagaku Ryoho; 2022 Sep; 49(9):994-996. PubMed ID: 36156023 [TBL] [Abstract][Full Text] [Related]
48. Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study. Shirota H; Komine K; Takahashi M; Takahashi S; Miyauchi E; Niizuma H; Tada H; Shimada M; Niihori T; Aoki Y; Sugiyama I; Kawamura M; Yasuda J; Suzuki S; Iwaya T; Saito M; Saito T; Shibata H; Furukawa T; Ishioka C Cancer Med; 2023 Mar; 12(5):6170-6181. PubMed ID: 36251535 [TBL] [Abstract][Full Text] [Related]
49. Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine. McGowan ML; Settersten RA; Juengst ET; Fishman JR Urol Oncol; 2014 Feb; 32(2):187-92. PubMed ID: 24445286 [TBL] [Abstract][Full Text] [Related]
50. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. Huang RSP; Haberberger J; McGregor K; Mata DA; Decker B; Hiemenz MC; Lechpammer M; Danziger N; Schiavone K; Creeden J; Graf RP; Strowd R; Lesser GJ; Razis ED; Bartsch R; Giannoudis A; Bhogal T; Lin NU; Pusztai L; Ross JS; Palmieri C; Ramkissoon SH Oncologist; 2021 Oct; 26(10):835-844. PubMed ID: 34105210 [TBL] [Abstract][Full Text] [Related]
51. Caregiver Burden, Psychological Distress and Quality of Life among Informal Caregivers of Patients with Head and Neck Cancer: A Longitudinal Study. Van Hof KS; Hoesseini A; Dorr MC; Verdonck-de Leeuw IM; Jansen F; Leemans CR; Takes RP; Terhaard CHJ; Baatenburg de Jong RJ; Sewnaik A; Offerman MPJ Int J Environ Res Public Health; 2022 Dec; 19(23):. PubMed ID: 36498377 [TBL] [Abstract][Full Text] [Related]
52. The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan. Sunami K; Naito Y; Aimono E; Amano T; Ennishi D; Kage H; Kanai M; Komine K; Koyama T; Maeda T; Morita S; Sakai D; Kohsaka S; Tsuchihara K; Yoshino T Int J Clin Oncol; 2021 Mar; 26(3):443-449. PubMed ID: 33385275 [TBL] [Abstract][Full Text] [Related]
53. [Current Status and Issues of Companion Diagnostics in Cancer Genomic Medicine]. Kanai M Gan To Kagaku Ryoho; 2024 Apr; 51(4):388-391. PubMed ID: 38644302 [TBL] [Abstract][Full Text] [Related]
54. Palliative care experiences of adult cancer patients from ethnocultural groups: a qualitative systematic review protocol. Busolo D; Woodgate R JBI Database System Rev Implement Rep; 2015 Jan; 13(1):99-111. PubMed ID: 26447011 [TBL] [Abstract][Full Text] [Related]
55. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584 [TBL] [Abstract][Full Text] [Related]
56. [Development of a System for Providing Cancer Genomic Medicine in Hokkaido-From the Standpoint of a Designated Core Hospital for Cancer Genomic Medicine]. Kinoshita I; Kikuchi J; Ohhara Y; Amano T; Akita H Gan To Kagaku Ryoho; 2021 Jul; 48(7):882-886. PubMed ID: 34267021 [TBL] [Abstract][Full Text] [Related]
57. The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey. Thavaneswaran S; Ballinger M; Butow P; Meiser B; Goldstein D; Lin F; Napier C; Thomas D; Best M Oncotarget; 2021 Oct; 12(21):2169-2176. PubMed ID: 34676049 [TBL] [Abstract][Full Text] [Related]
58. Physician interpretation of genomic test results and treatment selection. Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790 [TBL] [Abstract][Full Text] [Related]
59. Somatic Mutation Analysis of Human Cancers: Challenges in Clinical Practice. Tsongalis GJ; Coleman WB J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S60-S66. PubMed ID: 28921651 [TBL] [Abstract][Full Text] [Related]
60. The relationship between psychological distress and impairment of disease-specific quality-of-life compared between liquid sclerocompression therapy and invasive treatments in patients with superficial venous disease during a one-year follow-up. Krasznai AG; Catarinella FS; Houtermans-Auckel J; Nieman F; Wittens I; Mooij MC; Wittens CH Phlebology; 2021 Oct; 36(9):719-730. PubMed ID: 34039109 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]